Osteoglycin and Bone—a Systematic Review
Purpose of Review
Bone turnover is a regulated process. Osteoglycin is suggested to have an important impact on bone function but may also affect cardiovascular and metabolic functions. This review investigates the action of osteoglycin in bone as well as its potential endocrine effects.
Osteoglycin is expressed by several tissues including bone and muscle. Some studies suggest that osteoglycin increases osteoblast differentiation whereas others suggest that osteoglycin decreases osteoblast differentiation. Thus, findings on the influence of osteoglycin in bone are conflicting. A recent study found increased bone mass in osteoglycin deficient mice. Another study reported that osteoglycin is a marker of low bone mineral density and vertebral fractures in women with type 2 diabetes. Furthermore, clinical studies link osteoglycin to insulin resistance and cardiovascular disease.
Osteoglycin may be a novel marker of a muscle, pancreatic, and bone axis. However, current evidence is limited and further research investigating osteoglycin in both a pre-clinical and a clinical setting is needed.
KeywordsBone Osteoglycin Insulin resistance Bone turnover
Compliance with Ethical Standards
Conflict of Interest
Jakob Starup-Linde reports personal fees from Gilead Sciences Denmark and Eli Lilly Denmark.
Rikke Viggers and Aase Handberg declare no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 7.Szulc P, Bauer DC, Eastell R editors. Primer on the metabolic bone diseases and disorders of mineral metabolism chapter 35, biochemical markers of bone turnover in osteoporosis (pages 297–306). Eighth Edition, Editor(s): Clifford J. Rosen ed. Print ISBN: 9781118453889, Online ISBN: 9781118453926, DOI: https://doi.org/10.1002/9781118453926; 19 JUL 2013.
- 13.Hall JE, Guyton AC. Guyton and Hall textbook of medical physiology. 12nd ed. Philadelphia: Saunders/Elsevier; 2011.Google Scholar
- 24.Starup-Linde J, Vestergaard P. Biochemical bone turnover markers in diabetes mellitus - a systematic review. Bone. 2015.Google Scholar
- 25.• Chen X, Chen J, Xu D, Zhao S, Song H, Peng Y. Effects of osteoglycin (OGN) on treating senile osteoporosis by regulating MSCs. BMC Musculoskelet Disord. 2017;18(1):423-017–1779-7. Osteoglycin over-expression increases bone formation markers in bone marrow mesenchymal stem cells.Google Scholar
- 27.Moustafa A, Sugiyama T, Prasad J, Zaman G, Gross TS, Lanyon LE, et al. Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered. Osteoporos Int. 2012;23(4):1225–34.CrossRefGoogle Scholar
- 30.Tasheva ES, Koester A, Paulsen AQ, Garrett AS, Boyle DL, Davidson HJ, et al. Mimecan/osteoglycin-deficient mice have collagen fibril abnormalities. Mol Vis. 2002;8:407–15.Google Scholar
- 31.•• Lee NJ, Ali N, Zhang L, Qi Y, Clarke I, Enriquez RF, et al. Osteoglycin, a novel coordinator of bone and glucose homeostasis. Mol Metab. 2018;13:30–44. In this study osteoglycin is shown to regulate insulin secretion and insulin resistance. Furthermore osteoglycin deficient mice presented with increased bone mass. Google Scholar
- 32.•• Tanaka KI, Kanazawa I, Kaji H, Sugimoto T. Association of osteoglycin and FAM5C with bone turnover markers, bone mineral density, and vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Bone. 2017;95:5–10. Circulating osteoglycin in humans is associated with prevalent vertebral fractures and low bone mineral density. Google Scholar
- 35.Shanahan CM, Cary NR, Osbourn JK, Weissberg PL. Identification of osteoglycin as a component of the vascular matrix. Differential expression by vascular smooth muscle cells during neointima formation and in atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 1997;17(11):2437–47.CrossRefGoogle Scholar
- 40.• Deckx S, Heggermont W, Carai P, Rienks M, Dresselaers T, Himmelreich U, et al. Osteoglycin prevents the development of age-related diastolic dysfunction during pressure overload by reducing cardiac fibrosis and inflammation. Matrix Biol. 2018;66:110–24. This study suggests that osteoglycin protects from diastolic dysfunction due to cardiac fibrosis, which developed in osteoglycin deficient mice. Google Scholar
- 41.Cheng JM, Akkerhuis KM, Meilhac O, Oemrawsingh RM, Garcia-Garcia HM, van Geuns RJ, et al. Circulating osteoglycin and NGAL/MMP9 complex concentrations predict 1-year major adverse cardiovascular events after coronary angiography. Arterioscler Thromb Vasc Biol. 2014 May;34(5):1078–84.CrossRefGoogle Scholar
- 42.• Baek SH, Cha RH, Kang SW, Park CW, Cha DR, Kim SG, et al. Higher serum levels of osteoglycin are associated with all-cause mortality and cardiovascular and cerebrovascular events in patients with advanced chronic kidney disease. Tohoku J Exp Med. 2017;242(4):281–90. In this study osteoglycin is associated with cardiovascular events and mortality and may thus be a marker of cardiovascular disease. Google Scholar
- 47.Hygum K, Starup-Linde J, Harslof T, Vestergaard P, Langdahl BL. Mechanisms in endocrinology: diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis. Eur J Endocrinol 2017;176(3):R137-R157.Google Scholar
- 48.Starup-Linde J, Frost M, Vestergaard P. Abrahamsen B. Calcif Tissue Int: Epidemiology of fractures in diabetes; 2016.Google Scholar